| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| February 15, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 45,000 | $0.21 | 145,081 | |
| February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | $2.49 | 145,000 | |
| January 19, 2009 | VP & Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,666 | $2.72 | 145,000 | |
| March 23, 2011 | CEO | Form 4 | Conversion of derivative security | 17,083 | $2.40 | 143,745 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,000 | -- | 143,689 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 70,000 | -- | 143,689 | |
| October 7, 2016 | Director, Chairman, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 10,000 | $1.14 | 143,021 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,000 | -- | 140,118 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 70,000 | -- | 140,118 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,000 | -- | 139,880 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 70,000 | -- | 139,880 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,000 | -- | 139,737 | |
| June 15, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 70,000 | -- | 139,737 | |
| February 25, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,000 | -- | 139,689 | |
| November 14, 2005 | President, CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 76,645 | $0.33 | 139,145 | |
| May 13, 2009 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 15,000 | $3.90 | 137,562 | |
| February 25, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,000 | -- | 136,118 | |
| February 25, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,000 | -- | 135,880 | |
| February 25, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,000 | -- | 135,737 | |
| February 2, 2016 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 135,551 | |
| January 19, 2009 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,666 | $2.72 | 134,912 | |
| October 3, 2019 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,000 | -- | 133,689 | |
| January 19, 2009 | VP & Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,667 | $2.72 | 133,334 | |
| August 16, 2016 | Director, Chairman, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $1.25 | 133,021 | |
| September 6, 2016 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 12,665 | -- | 131,551 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
